![](https://medcitynews.com/wp-content/uploads/sites/7/2019/06/GettyImages-1129146997.jpg)
Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.